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We read with great interest a recent paper by Korzeniewski 
et al. [1] reporting the seroprevalence of hepatitis E virus (HEV) 
in Polish soldiers who were participants in military operations 
in Asia and Africa. The Authors found the presence of anti-HEV 
IgG antibodies (including borderline result in one soldier) in 
only 7.1% (n = 18) out of 253 participants of the study (6.3% 
when considering a confirmatory assay).
However, we think that due to the low sensitivity of the 
version of the Euroimmun assay used by Korzeniewski et 
al. [1] the seroprevalence of HEV reported in the discussed 
paper is severely underestimated.
We have recently compared anti-HEV IgG prevalence in 
blood donors (BDs) and HIV patients from Greater Poland 
region, west-central Poland, with both Euroimmun (original 
and updated cut-offs) and Wantai tests [2]. Our results 
demonstrate that HEV seroprevalence significantly changes 
(increases) after such a re-assessment. In brief, anti-HEV IgG 
were found in 4.6% (original cut-off of the Euroimmun assay, 
identical to that used in the study by Korzeniewski et al. [1]) 
vs. 22.9% (lowered cut-off, as suggested by Norder et al. 
[3]) out of 153 BDs and in 5.8% (original cut-off) vs. 18.3% 
(lowered cut-off) out of 104 HIV patients. More importantly, 
in both groups, HEV seroprevalence was substantially lower 
when assessed with the Euroimmun vs. Wantai assay. 
Low sensitivity of the older version of the Euroimmun 
assay in comparison to some other assays (including the 
highly-sensitive and partially-validated Wantai assay) was 
also shown by others [3–5].
Additionally, among Polish BDs who were assessed in 
a recent nationwide investigation [6] using the Wantai assay, 
HEV seroprevalence was considerably higher than in Polish 
soldiers serving in harsh environmental conditions in highly 
endemic areas of the world. It was also true when taking 
into account age as a factor potentially influencing the pres-
ence of anti-HEV IgG antibodies. In more details, in the study 
by Grabarczyk et al. [6] HEV seroprevalence in BDs aged 
28–57 varied from 42.7% in those aged 28–37 to 60.8% in per-
sons aged 48–57. In our view, it is highly unlikely that such a large 
discrepancy between BDs and soldiers reflects a real situation. 
Moreover, we hypothesize that anti-HEV IgG resulting 
from local exposure to HEV but not detected by a non-sensi-
tive assay (as that used by Korzeniewski et al. [1]) could be 
the source of protective immunity for Polish soldiers when 
serving in countries of Africa and Asia. 
It should be noted that despite the more common symptom-
atic course of hepatitis E caused by human-specific HEV-1 or 
HEV-2 prevalent in highly endemic areas (versus HEV-3 which is 
predominant in industrialised countries) only a few (n = 3) soldiers 
experienced icteric disease (in all of them anti-HEV IgG antibodies 
were undetectable). On the other hand, 15 out of 16 HEV-sero-
positive soldiers had no symptoms consistent with viral hepatitis.
For all these reasons, we think that it would be very 
interesting to know the seroprevalence of HEV in soldiers 
from the Polish Special Forces evaluated after implemen-
tation of the lowered cut-off value of the Euroimmun assay 
or, preferably, with the use of more accurate test. 
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